The article responds to comments and criticisms regarding their previous report on a patient with severe ulcerative colitis who responded to ustekinumab. They address concerns about endoscopic images, disease extension, medication dosage, histopathological findings and the need to clarify the underlying type of inflammatory bowel disease for recommending treatment intervals.